CYTK · NASDAQ · STOCK
Cytokinetics
$76.72
52W $32.89 – $88.31
60/100
$9.55B
-10.6
0.38
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is CYTK Bullish or Bearish?
Bullish.
Innellis AI committee rates Cytokinetics (CYTK) Buy with a composite score of 60/100
, based on 5 analysts with 60% agreement.
Last updated August 08, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +15.10 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -4.90 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 450.6% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 15.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 450.6% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- Price-to-book of 15.7x prices in significant intangible value — Value
- ROE of only -131.2% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 08, 2026
Overall Committee Score
60/100
Agreement
60%
Analysts
5
Conviction
Contested
Sector Rank
Top 46%
of 95 Healthcare peers
Value Analyst
bearish
30
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 15.7x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 450.6% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 20 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 4 existing position pair(s) are highly correlated already
Investment Thesis Evolution
Committee score weakened from 67.4 to 59.9.
- High-conviction consensus weakened -- analysts became more divided.
- Committee agreement fell notably from 75% to 60%.
- New bearish signals: 2 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 2 appeared.
- New analyst(s) joined: Value Analyst.
Analyst-level changes:
- Growth Analyst: +1 bullish signal(s).
- News Analyst: +1 bullish signal(s).
- Value Analyst joined: bearish at 30.
Comparing 2026-08-07 to 2026-08-08 (1 day apart).
Technical Analysis
RSI (14)
39.3
Neutral
MACD Histogram
-0.400
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$66.72
Resistance
$80.01
Bollinger %B
0.06
Inside Bands
Price vs Moving Averages
EMA 9
$78.95
Below
EMA 21
$79.73
Below
EMA 50
$78.41
Below
EMA 200
$68.35
Above
Fundamental Analysis
Valuation
100
Growth
45
Profitability
50
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-10.6×
P/B Ratio
-58.44×
PEG Ratio
0.32
Dividend Yield
0.00%
52W High
$88.31
52W Low
$32.89
Quality & Growth
ROE
11900.0%
ROA
-5510.2%
Gross Margin
8497.3%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
-7.32
AI Fundamental Assessment
P/E ratio of -10.6 (inexpensive relative to a 15-40x range); Price-to-book of -58.4x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 119.0%; Return on assets of -55.1%; Net margin of -1259.9%; Gross margin of 85.0%; Current ratio of 6.66 (healthy short-term liquidity); Debt-to-equity of -7.32; Free cash flow per share is negative (-5.54); Most recent quarter beat estimates by 10.4%; 2 consecutive earnings beats; EPS growth accelerating (-11.3% -> +10.2% QoQ); Average YoY EPS growth of -33.9%; Analyst estimates falling over recent quarters
Get the Full CYTK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →